An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Thermo Fisher Scientific Prices Offering of Yen-Denominated Senior Notes
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Thermo Fisher Scientific (NYSE: TMO) has announced the pricing of a ¥109.5 billion offering of yen-denominated senior notes, including 0.853% notes due 2025 and 2.382% notes due 2052. The offering is set to close on or about October 20, 2022. Proceeds will be used for general corporate purposes like debt repayment, acquisitions, or capital expenditures. The notes will pay interest semi-annually and are being managed by Citigroup, Mizuho, MUFG, and SMBC. For further details, investors are encouraged to review related SEC filings.
Diverse range of maturities (2025 to 2052) offers flexibility in capital management.
Proceeds intended for strategic purposes like acquisitions and debt refinancing which could enhance growth.
Negative
The offering may increase total debt levels, impacting financial leverage.
Interest payments on new notes could strain cash flow if not managed properly.
WALTHAM, Mass.--(BUSINESS WIRE)--
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) the world leader in serving science, announced today that it has priced an offering of ¥109.5 billion aggregate principal amount (the “Offering”) of the following yen-denominated notes, each issued at par:
¥22,300,000,000 aggregate principal amount of its 0.853% Senior Notes due 2025 (the “2025 Notes”),
¥28,900,000,000 aggregate principal amount of its 1.054% Senior Notes due 2027 (the “2027 Notes”),
¥4,700,000,000 aggregate principal amount of its 1.279% Senior Notes due 2029 (the “2029 Notes”),
¥6,300,000,000 aggregate principal amount of its 1.490% Senior Notes due 2032 (the “2032 Notes”),
¥14,600,000,000 aggregate principal amount of its 2.069% Senior Notes due 2042 (the “2042 Notes”), and
¥33,300,000,000 aggregate principal amount of its 2.382% Senior Notes due 2052 (the “2052 Notes” and, collectively with the 2025 Notes, the 2027 Notes, the 2029 Notes, the 2032 Notes and the 2042 Notes, the “Notes”).
The Offering is expected to close on or about October 20, 2022, subject to customary closing conditions. The Notes will pay interest on a semi-annual basis.
Thermo Fisher intends to use the net proceeds of the Offering for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.
The joint book-running managers for the Offering are Citigroup Global Markets Limited, Mizuho Securities USA LLC, MUFG Securities EMEA plc and SMBC Nikko Securities America, Inc.
The Offering is being made pursuant to an effective registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (the “SEC”). Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the Offering and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Offering will arrange to send you the prospectus if you request it by calling Citigroup Global Markets Limited at 1-800-831-9146, Mizuho Securities USA LLC at 1-866-271-7403, MUFG Securities EMEA plc at +44-20-7577-2206 or SMBC Nikko Securities America, Inc. at 1-888-868-6856.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Thermo Fisher’s intended use of proceeds. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the prospectus dated February 25, 2022 and the prospectus supplement dated October 11, 2022 related to the Offering, which is on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings,” and the documents incorporated by reference into the prospectus and prospectus supplement. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
